← Back to Search

Biguanide

Metformin Response During Meal Test for Type 2 Diabetes (SCRAMBLED EGGS Trial)

N/A
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-79
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 8 of the study
Awards & highlights

SCRAMBLED EGGS Trial Summary

This trial looks at how different genes affect how humans respond to food and medication for diabetes.

Who is the study for?
This trial is for adults aged 18-79 who can consent to genetic research. It's not for those with kidney issues, contraindications to metformin, recent or planned medication changes, other study participation, intestinal malabsorption conditions, liver disease, pregnancy risk, or on diabetes medications.Check my eligibility
What is being tested?
The study tests how genes affect responses to a special meal and metformin (a common diabetes drug). Participants will eat a mixed meal and take metformin while researchers observe differences in response between gene carriers linked to type 2 diabetes.See study design
What are the potential side effects?
Metformin may cause digestive upset like diarrhea or nausea; it might also lead to vitamin B12 deficiency over time. Rarely it could cause a serious condition called lactic acidosis especially if there are kidney problems.

SCRAMBLED EGGS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 79 years old.

SCRAMBLED EGGS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8 of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 8 of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response to the Mixed Meal Tolerance Test
Secondary outcome measures
Response to Metformin
Other outcome measures
Response to a Mixed Meal Tolerance Test after Metformin

SCRAMBLED EGGS Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Carriers of the SLC16A11 risk alleleActive Control2 Interventions
Day 1: Mixed Meal Tolerance Test Day 3-7: 500mg metformin, twice daily Day 8: Mixed Meal Tolerance Test in presence of Metformin
Group II: Non-carriers of the SLC16A11 risk allelePlacebo Group2 Interventions
Day 1: Mixed Meal Tolerance Test Day 3-7: 500mg metformin, twice daily Day 8: Mixed Meal Tolerance Test in presence of Metformin

Find a Location

Who is running the clinical trial?

Instituto Carlos Slim de la SaludUNKNOWN
Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,197,338 Total Patients Enrolled
3 Trials studying Metabolism
253,639 Patients Enrolled for Metabolism
Broad InstituteOTHER
19 Previous Clinical Trials
15,260 Total Patients Enrolled

Media Library

Metformin (Biguanide) Clinical Trial Eligibility Overview. Trial Name: NCT02087826 — N/A
Metabolism Research Study Groups: Carriers of the SLC16A11 risk allele, Non-carriers of the SLC16A11 risk allele
Metabolism Clinical Trial 2023: Metformin Highlights & Side Effects. Trial Name: NCT02087826 — N/A
Metformin (Biguanide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02087826 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~92 spots leftby Apr 2025